Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells
Introduction Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antige...
Saved in:
Main Authors: | Massimo Fantini (Author), Kwong Y. Tsang (Author), Philip M. Arlen (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis
by: Junying Wang, et al.
Published: (2023) -
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
by: Shifen Wang, et al.
Published: (2023) -
Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022) -
Monoclonal Antibodies
Published: (2021) -
Monoclonal Antibodies
by: Christian Klein (Ed.)
Published: (2018)